Literature DB >> 9742324

Chronic aortic regurgitation. Role of medical therapy and optimal timing for surgery.

R O Bonow1.   

Abstract

Aortic valve replacement should be performed once significant symptoms develop. Lacking important symptoms, operation should also be performed in patients with aortic regurgitation who manifest consistent and reproducible evidence of either LV contractile dysfunction at rest or extreme LV dilation. Noninvasive imaging techniques should play a major role in this evaluation. An important clinical decision, such as recommending aortic valve replacement in the asymptomatic patient, should not be based on a single echocardiographic or radionuclide angiographic measurement alone. When these data consistently indicate impaired contractile function at rest or extreme LV dilation on repeat measurements, however, operation is indicated in the asymptomatic patient. This strategy should reduce the likelihood of irreversible LV dysfunction in these patients and enhance long-term postoperative survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9742324     DOI: 10.1016/s0733-8651(05)70025-4

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  4 in total

Review 1.  The medical management of valvar heart disease.

Authors:  N A Boon; P Bloomfield
Journal:  Heart       Date:  2002-04       Impact factor: 5.994

Review 2.  Indications for surgery for aortic regurgitation.

Authors:  Vuyisile T Nkomo
Journal:  Curr Cardiol Rep       Date:  2003-03       Impact factor: 2.931

3.  Management of Chronic Aortic Regurgitation.

Authors:  Donald D. Glower
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-12

4.  The role of cardiopulmonary exercise test in mitral and aortic regurgitation: it can predict post-operative results.

Authors:  Hyun Joong Kim; Seung Woo Park; Byung Ryul Cho; Sun Hee Hong; Pyo Won Park; Kyung Pyo Hong
Journal:  Korean J Intern Med       Date:  2003-03       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.